10x Genomics (NASDAQ:TXG) said it has begun shipping the first two products powered by its next-generation GEM-X technology architecture. The life sciences technology company said the first products ...

10x Genomics is seeking additional injunctions to protect its intellectual property Since its founding in 2012, 10x Genomics has focused on a broad array of key technologies and intellectual property ...

PLEASANTON, Calif., March 3, 2025 /PRNewswire/ — 10x Genomics (Nasdaq: TXG), a leader in single-cell and spatial biology, today provided an update on its patent litigation with Parse Biosciences.

PLEASANTON, Calif., Feb. 24, 2021 (GLOBE NEWSWIRE) -- 10x Genomics, Inc. (Nasdaq: TXG) today detailed a slew of new products and announced the acquisition of Copenhagen-based Tetramer Shop at its ...

10x Genomics said it will use a combined $125 million in new funding toward the development and launch of new products, as well as continued expansion of its commercial operations. The new funding ...

SEATTLE--(BUSINESS WIRE)--Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced that the Patent Trial and Appeal Board (PTAB) of the United ...

10x Genomics has reeled in $50 million in series D cash. The round moves 10x’s VC haul up past the $180 million mark, setting it up to introduce a range of add-ons to its long-read sequencing and ...

On October 21, 10x Genomics, Inc. and Prognosys Biosciences, Inc. filed a complaint for patent infringement against Illumina, ...

(Reuters) - Gene-sequencing company 10x Genomics Inc sued startup Parse Biosciences Inc in Delaware federal court Wednesday, alleging its gene-analysis kits infringe patents related to 10x's Chromium ...

10x Genomics (NASDAQ:TXG) announced on Monday that its ATAC-Seq patents were found valid and infringed in its patent litigation with Parse Biosciences. On February 25, 2025, a consent agreement was ...